Drugs / Telotristat
Telotristat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04543955 | Sep 2021 → Jun 2022 | neuroendocrine neoplasm | Lowell Anthony, MD | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-11-09 | TerSera Therapeutics LLC | Results TerSera® Presents Patient-Reported Clinical and Productivity Outcomes Associated with Xermelo® (Telotristat Ethyl): Long-Term Registry Trial of Patients with Carcinoid Syndrome Diarrhea tersera.com ↗
Patients receiving Xermelo reported improved clinical outcomes, satisfaction with control of carcinoid syndrome (CS) symptoms, weight gain or maintenance, and reduced work productivity and activity impairment (WPAI) after 6 months of treatment.1 |
| 2021-10-27 | TerSera Therapeutics LLC | Results TerSera® Announces Publication of Real-World Study on Xermelo® (Telotristat Ethyl) in Patients with Carcinoid Syndrome Diarrhea tersera.com ↗
Patients reported significant improvements in all symptoms of CSD after 3 months of Xermelo therapy. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-11-09 | TerSera Therapeutics LLC | TerSera® Presents Patient-Reported Clinical and Productivity Outcomes Associated with Xermelo® (Telotristat Ethyl): Long-Term Registry Trial of Patients with Carcinoid Syndrome Diarrhea tersera.com ↗ |
| 2021-10-27 | TerSera Therapeutics LLC | TerSera® Announces Publication of Real-World Study on Xermelo® (Telotristat Ethyl) in Patients with Carcinoid Syndrome Diarrhea tersera.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Telotristat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04543955 ↗ |
| Known as | LP 778902 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103855 ↗ |
| Known as | LX-3033 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103855 ↗ |
| Action | Inhibit | “This trial tests the hypothesis that inhibition of serotonin production with Telotristat will lead to cytostatic effects on neuroendocrine tumors” NCT04543955 ↗ |
| Modality | Small molecule | — CHEMBL2103855 ↗ |
| Route | Oral | “oral Telotristat at 750mg per day (250mg TID)” NCT04543955 ↗ |